The delisting overhang is removed, which may attract incremental buying from funds restricted from holding sub-$1 stocks. Monitor for any follow-on equity offering that often accompanies regained compliance, as the company may seek to raise capital while the stock is above $1.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 15 $6.86entry
- T+1 · 2mo ago +1.53%α +1.21% · $6.97
- T+5 · 8w ago −63.70%α −64.52% · $2.49
- T+20 · 5w ago −68.66%α −71.64% · $2.15
- T+44 · todayOpen
- T+60 · in 22d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Longeveron received written notification from Nasdaq on September 11, 2026, confirming that its Class A common stock had a closing bid price of $1.00 or greater for 10 consecutive business days (August 27 to September 10, 2026), thereby regaining compliance with the $1.00 minimum bid price requirement. The Nasdaq matter is now closed, removing the immediate delisting risk that had been pending since September 2025.
Key Facts
- Longeveron received a Nasdaq deficiency notice on September 22, 2025 for non-compliance with the $1.00 minimum bid price rule.
- An initial 180-day compliance period expired March 23, 2026; a second 180-day extension ran until September 21, 2026.
- On September 11, 2026, Nasdaq confirmed the stock closed at $1.00 or above for 10 consecutive business days (Aug 27, Sep 10, 2026).
- The Nasdaq minimum bid price compliance matter is now closed.
Financial Impact
No direct financial impact; removal of delisting risk preserves Nasdaq listing and avoids potential OTC trading and liquidity loss.
Risk Factors
- Regained compliance does not address the underlying business fundamentals or cash runway; the stock could again fall below $1.
- The company may still need to raise capital, potentially diluting shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-099712 |
| Document: 0001213900-26-099712-index-headers.html | 0001213900-26-099712 |
| Document: 0001213900-26-099712-index.html | 0001213900-26-099712 |
| Document: 0001213900-26-099712.txt | 0001213900-26-099712 |
Track record
22 reports on LGVN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers